The revised JBI critical appraisal tool for the assessment of risk of bias for analytical cross-sectional studies
Abstract
Cross-sectional studies are a useful observational study design that provides a snapshot of a population's health status at a specific moment in time. Analytical cross-sectional studies are often included in systematic reviews investigating the etiology or risk of diseases, and descriptive cross-sectional studies are often used to determine the prevalence of a disease. As required of all studies that meet eligibility criteria for a systematic review, analytical cross-sectional studies should be subjected to appropriate critical appraisal of their methodological quality to determine the risk of bias. The JBI Effectiveness Methodology Group is currently undertaking a comprehensive revision of the entire suite of JBI critical appraisal tools to align with recent advances in risk of bias assessment. This paper presents the revised critical appraisal tool for risk of bias assessment of analytical cross-sectional studies. Applying tools such as the revised JBI tools within systematic reviews allows for end users to make informed decisions using the evidence. We discuss major changes from the previous iterations of this tool and justify these changes within the context of the broader advancements to risk-of-bias assessment science. We also offer practical guidance for the use of this revised tool, and provide examples for interpreting the results of risk-of-bias assessment for analytical cross-sectional studies to support reviewers including these studies in their systematic…
Read the paper
Related studies
- Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics
- Challenges in Chagas Disease Drug Development
- T Cell Specificity: A Great Challenge in Chagas Disease
- Benznidazole treatment leads to DNA damage in Trypanosoma cruzi and the persistence of rare widely dispersed non-replicative amastigotes in mice
- Rapid Molecular Detection of Terbinafine-resistant Dermatophytes
- Identifying novel drugs with new modes of action for neglected tropical fungal skin diseases (fungal skinNTDs) using an Open Source Drug discovery approach
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.